 |
인쇄하기
취소
|
Local first hypertension +hyperlipidemia combination ‘Robelito’ available in the market soon
Hanmi – Sanofi Joint development – appointed reexamination in 6 years by MFDA
(Newspaper Chungnyun Doctor)
The fixed dose combination (FDC) of hypertension drug Irbesratan and hyperlipidemia drug Atorvastatin is going to launch in Korea.
Hanmi and Sanofi revealed that the marketing authorization of Robelito which had been developed jointly with Hanmi and Sanofi obtained from MFDA.
T...
(Newspaper Chungnyun Doctor)
The fixed dose combination (FDC) of hypertension drug Irbesratan and hyperlipidemia drug Atorvastatin is going to launch in Korea.
Hanmi and Sanofi revealed that the marketing authorization of Robelito which had been developed jointly with Hanmi and Sanofi obtained from MFDA.
T...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.